Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review

Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review

BACKGROUND: Memantine is licensed for moderate-to-severe Alzheimer's disease (AD). National Institute for Clinical Excellence (NICE) guidance does not recommend the use of memantine in combination with cholinesterase inhibitors (acetylcholinesterase inhibitor (AChEI)). The underpinning meta-an...

Bibliografski detalji
Glavni autori:	Farrimond, L, Roberts, E, McShane, R
Format:	Journal article
Jezik:	English
Izdano:	BMJ Publishing Group 2012

Slični predmeti

Systematic Review and Meta-Analysis of Combination Therapy with Cholinesterase Inhibitors and Memantine in Alzheimer’s Disease and Other Dementias
od: Taim Muayqil, i dr.
Izdano: (2012-11-01)

The pharmacological treatment of Alzheimer's disease with cholinesterase inhibitors and memantine
od: Wilcock, G
Izdano: (2007)

Important Error in ‘Systematic Review and Meta-Analysis of Combination Therapy with Cholinesterase Inhibitors and Memantine in Alzheimer's Disease and Other Dementias' by Muayqil and Camicioli
od: Pierre N. Tariot, i dr.
Izdano: (2014-05-01)

Lack of evidence for the efficacy of memantine in mild Alzheimer disease.
od: Schneider, L, i dr.
Izdano: (2011)

Alzheimer’s dementia: budget impact and cost-utility analysis of a combination treatment with a cholinesterase inhibitor and memantine in Switzerland
od: Alena M. Pfeil, i dr.
Izdano: (2012-11-01)

Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and Dementia with Lewy bodies.
od: Gustavsson, A, i dr.
Izdano: (2009)

Lack of evidence for the efficacy of memantine in mild Alzheimer disease
od: Schneider, L, i dr.
Izdano: (2011)

Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer's disease: a meta-analysis
od: Dominik Glinz, i dr.
Izdano: (2019-06-01)

Donepezil and memantine for moderate-to-severe Alzheimer's disease
od: Howard, R, i dr.
Izdano: (2012)

Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer’s Treatment: Systematic Review
od: Maryam N. ALNasser, i dr.
Izdano: (2025-02-01)

Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis.
od: Shinji Matsunaga, i dr.
Izdano: (2015-01-01)

Meta-analysis of memantine: summary and commentary on the Cochrane Collaboration's systematic review.
od: Mcshane, R, i dr.
Izdano: (2005)

Electrocardiographic Effects of Cholinesterase Inhibitors in Patients with Alzheimer’s Disease
od: Ayşe ÇOLAK, i dr.
Izdano: (2022-12-01)

Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer’s disease cohort
od: Wattmo Carina, i dr.
Izdano: (2012-11-01)

Memantine, Donepezil, or Combination Therapy—What is the best therapy for Alzheimer’s Disease? A Network Meta‐Analysis
od: Jiaxun Guo, i dr.
Izdano: (2020-11-01)

A systematic review of economic evaluations of the use of memantine alone or combined with donepezil for moderate to severe Alzheimer’s disease
od: Ione Ayala Gualandi de Oliveira, i dr.
Izdano: (2019-11-01)

Memantine for dementia.
od: Mcshane, R, i dr.
Izdano: (2006)

Anti-Cholinesterase Combination Drug Therapy as a Potential Treatment for Alzheimer’s Disease
od: Hafsa Amat-ur-Rasool, i dr.
Izdano: (2021-02-01)

Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer's disease.
od: Chalmers, K, i dr.
Izdano: (2009)

Odor identification impairment and cholinesterase inhibitor treatment in Alzheimer's disease
od: Jeffrey N. Motter, i dr.
Izdano: (2021-01-01)

CHRNA7 polymorphisms and response to cholinesterase inhibitors in Alzheimer's disease.
od: Pei-Hsuan Weng, i dr.
Izdano: (2013-01-01)

Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients
od: Martina Zimmermann, i dr.
Izdano: (2005-06-01)

Synthesis and Biological Evaluation of New Cholinesterase Inhibitors for Alzheimer’s Disease
od: Weiam Hussein, i dr.
Izdano: (2018-08-01)

Real-world effectiveness, its predictors and onset of action of cholinesterase inhibitors and memantine in dementia: retrospective health record study
od: Vaci, N, i dr.
Izdano: (2020)

Cholinesterase inhibitors and memantine are associated with a reduced mortality in nursing home residents with dementia: a longitudinal observational study
od: Charlotte Havreng-Théry, i dr.
Izdano: (2024-05-01)

Memantine Derivatives as Multitarget Agents in Alzheimer’s Disease
od: Giambattista Marotta, i dr.
Izdano: (2020-09-01)

Exploring Mannosylpurines as Copper Chelators and Cholinesterase Inhibitors with Potential for Alzheimer’s Disease
od: Ignazio Schino, i dr.
Izdano: (2022-12-01)

Correction: Cholinesterase inhibitors and memantine are associated with a reduced mortality in nursing home residents with dementia: a longitudinal observational study
od: Charlotte Havreng-Théry, i dr.
Izdano: (2024-08-01)

Discontinuing Donepezil or Starting Memantine for Alzheimer's Disease Reply
od: Howard, R, i dr.
Izdano: (2012)

Update on the use of memantine in Alzheimer&rsquo;s disease
od: Robert J van Marum
Izdano: (2009-03-01)

Memantine-induced Myoclonus in a Patient with Alzheimer Disease
od: Aditya A. Murgai, i dr.
Izdano: (2015-08-01)

Management of moderate to severe Alzheimer’s disease: Focus on memantine
od: Evangelyn Dominguez, i dr.
Izdano: (2011-12-01)

Dual Action of Memantine in Alzheimer Disease: A Hypothesis
od: Tzong-Yuan Wu, i dr.
Izdano: (2009-09-01)

QuinoxalineTacrine QT78, a Cholinesterase Inhibitor as a Potential Ligand for Alzheimer’s Disease Therapy
od: Eva Ramos, i dr.
Izdano: (2019-04-01)

Derivatives of Amodiaquine as Potent Human Cholinesterases Inhibitors: Implication for Treatment of Alzheimer’s Disease
od: Ana Matošević, i dr.
Izdano: (2024-11-01)

The effect of cholinesterase inhibitors on sleep in the patients with Alzheimer’s disease: an observational prospective study
od: Osman Korucu, i dr.
Izdano: (2018-01-01)

Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story
od: Lam Benjamin, i dr.
Izdano: (2009-12-01)

DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT.
od: Jones, R, i dr.
Izdano: (2009)

DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease – a multicentre RCT
od: Lindesay James, i dr.
Izdano: (2009-07-01)

Systematic Review of Cholinesterase Inhibitors on Cognition and Behavioral Symptoms in Patients of Chinese Descent with Alzheimer’s Disease, Vascular Dementia, or Mixed Dementia
od: Ka-Chun Leung, i dr.
Izdano: (2017-08-01)